Personalized Medicine in Acromegaly: The ACROFAST Study
An erratum to this article was published (J Clin Endocrinol Metab, 18 Dec 2024 ↗)
Authors' conclusion
Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
Study context
- Population
- Patients with acromegaly, 21 university hospitals
- Participants
- 85 patients
- Exposure
- Personalized biomarker-based protocol vs control protocol starting with first-generation SRLs
- Personalizedn = 45
- Controln = 40reference
- Outcome
- Effectiveness (hormonal control) and time-to-control
- Follow-up
- 12 months
Methodological detailsmulticentre (21 university hospitals)
- Multicentre (21 university hospitals)
Main finding
Hormonal control
HR for achieving hormonal control, adjusted by age and sex
2.53
CI 1.30–4.80
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Time to hormonal controlShorter time to control with Personalized | P = 0.01 |
Original publication
Personalized Medicine in Acromegaly: The ACROFAST Study. J Clin Endocrinol Metab. Published 29 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →